From CF To Big Pulmonary Markets: SpliSense’s Strategy To Make Inhaled RNA Work
SpliSense is the first company to show inhaled antisense oligos improve lung function in cystic fibrosis, validating its platform for larger COPD and asthma markets.
In Vivo - February 9, 2026

Siemens Healthineers CEO Bullish On Diagnostics Despite Market Pressure
Siemens Healthineers expects China-related pressure to continue into the second quarter, with diagnostics revenue declining more sharply in the year ahead.
Medtech Insight - February 9, 2026

Activ’Inside Takes Closer Look At Botanicals With Research Partnership
French manufacturer is teaming up with the University of Bordeaux to identify phytonutrients for potential use in dietary supplements.
HBW Insight - February 9, 2026

US FDA Warning Letters - December 2025-January 2026
Twenty-one companies received US FDA warning letters in December and January. About half were part of a crackdown on unregistered vendors of breast binders, while other recipients included Abbott and Magellan Diagnostics.
Medtech Insight - February 9, 2026

GE HealthCare Budgets China Decline Into 2026 As Backlog Anchors Growth Outlook
While executives expressed confidence in operational changes underway in China, they said those improvements were not enough to justify a more optimistic near-term forecast. As a result, GE HealthCare’s 3% to 4% total company organic growth guidance for 2026 assumes a decline in China.
Medtech Insight - February 9, 2026

Bio-Thera Partners With Avalon Pharma For Keytruda Biosimilar In Middle East
Bio-Thera has struck a deal with Saudi-based Avalon Pharma to commercialize its Keytruda rival, marking its start in immuno-oncology biosimilars for the MENA markets.
Generics Bulletin - February 9, 2026

Lilly Joins The In Vivo Cell Therapy Fray With Orna Acquisition
Orna’s lead candidate, ORN252, which targets CD19 positive autoimmune diseases, is expected to reach the clinic in 2026.
Scrip - February 9, 2026

Breckenridge Expands Injectables Portfolio Through Medichem Collaboration
Deal brings sterile fill-and-finish capacity from Medichem Solutions as Breckenridge continues to build its hospital portfolio.
Generics Bulletin - February 9, 2026

Deal-Making Quarterly Statistics, Q4 2025
During Q4, biopharma merger and acquisition deal value reached $94.8bn and drew in $74.7bn in potential deal value from alliances. Device company M&A values reached $3.5bn, while in vitro diagnostics and research tools players’ M&A activity totaled $39.8m.
In Vivo - February 9, 2026

Biogen’s Alisha Alaimo On The Company’s Next Big Commercial Build
Biogen’s president and head of North America talked to Scrip about the company’s commercial expansion into new areas in immunology and nephrology.
In Vivo - February 9, 2026

Sandoz And Former Parent Novartis Hit With Fresh US Generic Price-Fixing Suit
States allege Novartis and its former generics arm Sandoz colluded with rivals to keep generic drug prices high, then restructured the Sandoz business to limit antitrust liability.
Generics Bulletin - February 9, 2026

A Look At The Next Gen Obesity Pipeline Coming Out Of China
Scrip takes a look at the next generation of innovation in obesity medicines coming out of China and key assets originated in the country set to enter Phase III this year.
Scrip - February 9, 2026

Innovent, Lilly Partner On Oncology, Immunology Programs
Innovent continues to diversify cross-border collaboration approaches through a seventh alliance with Lilly, this time for oncology and immunology R&D.
Scrip - February 9, 2026

Quick Listen: Scrip’s Five Must-Know Things
In this week's episode: Merck looks to fill Keytruda’s shoes; Novartis aims to push through largest expiry period; Novo warns of steep sales decline; Pfizer bullish on obesity; and Lilly expects orforglipron success.
Scrip - February 9, 2026